# The RECAP2 Study: Midazolam and Psilocybin

> **NCT06692192** · PHASE1 · RECRUITING · sponsor: **University of Wisconsin, Madison** · enrollment: 60 (estimated)

## Conditions studied

- Psilocybin

## Interventions

- **DRUG:** Psilocybin
- **DRUG:** Psilocybin
- **DRUG:** Midazolam
- **DRUG:** Saline

## Key facts

- **NCT ID:** NCT06692192
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-07
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06692192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06692192, "The RECAP2 Study: Midazolam and Psilocybin". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06692192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*